Abstracts tagged "dermatomyositis"

Abstract Number: 2672 • ACR Convergence 2025
Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
Can Xia¹, Wanlong Wu¹, Yan Ye¹, Jingjing Li², Runci Wang¹, Wenwen Xu³, Zhiwei Chen¹, Yakai Fu², Xia Lyu¹, Kaiwen Wang¹, Wei Fan¹, Jia Li¹, Xiaodong Wang², Shuang Ye⁴ and Qiong Fu⁵, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5+DM) is a distinct and severe subtype of dermatomyositis, frequently complicated by interstitial lung disease (ILD). Among…
Abstract Number: 0298 • ACR Convergence 2025
Inter-rater Reliability of Hand-Held Dynamometry in Patients with Idiopathic Inflammatory Myopathy
Niladri Bhowmick¹, Shashank Suresh², Didem Saygin³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, ²Atrium Health, Charlotte, NC, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by symmetrical proximal muscle weakness. Accurate and reliable assessment of muscle strength is important for diagnosis, monitoring, and…
Abstract Number: 1212 • ACR Convergence 2025
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Maria Rosa Pellico¹, Cristina Bochicchio², Claudia Iannone³, Lekshmi Minikumari Rahulan⁴, Marco Fornaro⁵, Ilaria Cavazzana⁶, Edoardo Conticini⁷, Masataka Kuwana⁸, Akira Yoshida⁹, Silvia Cavalli², Silvia Grazzini⁷, Alessia Gatti¹⁰, Giulio Lopinto¹¹, Paolo Semeraro¹², Thomas Patrick Sheeran¹³, Florenzo Iannone¹⁴, Vikas Agarwal¹⁵, Roberto Caporali¹⁶, Nicoletta Del pAPA¹ and Latika Gupta¹⁷, ¹ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ²ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ³University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ⁵Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ⁶Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ¹¹Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, ¹²Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Italy, ¹³Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; Rheumatology Department, Walsall Manor Hospital, Walsall, UK, Wolverhampton, United Kingdom, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous diseases. One of the greatest challenges in IIM management is defining and predicting…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 2673 • ACR Convergence 2025
Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
Fatma Basibuyuk¹, Melih Yigithan Bahadir², Gokce Kenar Artin², Amac Kiray², Recep Bekis² and İsmail Sari², ¹Dokuz Eylul University, Izmir, Turkey, ²Dokuz Eylül University, İzmir, Izmir, Turkey
Background/Purpose: To characterize muscle involvement in idiopathic inflammatory myopathies (IIMs) using detailed anatomical segmentation and volumetric 18F-FDG PET/CT analysis, and to evaluate the prognostic value…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 2063 • ACR Convergence 2025
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Julie Paik¹, Andrea Young², Zuzana Bologna³, Will Kelly³, Chris Mecoli⁴, Jemima Albayda² and Lisa Christopher-Stine², ¹Johns Hopkins Rheumatology, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a chronic inflammatory myopathy characterized by muscle weakness and skin rashes, yet its full impact on patient-reported outcomes remains under-explored. We…
Abstract Number: PP02 • ACR Convergence 2025
When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
Kyanna Johnson, Lynn Wilson, Manuel Lubinus, Elisa Glass
Background/Purpose: My journey with dermatomyositis (DM) began abruptly in July 2024, when I was hit by sudden, severe muscle weakness after a GI infection. I…
Abstract Number: 0388 • ACR Convergence 2025
A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases
Michael Moore¹, Kaien Gu², Carol Cooke¹, Annaliese Tisseverasinghe¹ and Lily Lim¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) include systemic lupus erythematous (SLE), idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), Sjögren syndrome (SS), and systemic vasculitis (SV).…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 2068 • ACR Convergence 2025
Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
Michael George¹, Thomas Riley¹, Ellen Romich², Emily Holladay³, Tim Beukelman⁴, Shanette Daigle⁵, Amy Mudano⁵, Fenglong Xie⁶, Xiang Guo⁷, Nicole Kulisek⁸, Arne Yndestad⁹, Ashraf Chaudhary⁸ and Jeffrey Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Pfizer, Inc, New York, NY, ⁸Pfizer, Inc, Collegeville, PA, ⁹Pfizer Inc, Oslo, Norway, Oslo, Norway, ¹⁰Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Studies of idiopathic inflammatory myopathies (IIM) are often based on the analysis of single cohorts at academic centers. We aimed to identify potential gaps…
Abstract Number: 0822 • ACR Convergence 2025
Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
Kavya Sugur¹, Elizabeth Sloan², Emily Chong³, Sophia Matossian³, Katarina Kmetova⁴, Alyssa Rosek⁵, Christine Goudsmit⁶, Celine C. Berthier⁶, Pei-Suen Tsou³, Yu (Ray) Zuo³ and Jessica Turnier⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, ⁷University of Michigan, Saline, MI
Background/Purpose: Most children with juvenile dermatomyositis (JDM) have chronic disease despite multi-drug immunosuppression, highlighting the need for targeted therapies. Neutrophil extracellular traps (NETs) are key…
Abstract Number: 1740 • ACR Convergence 2025
A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
Emily Chong¹, Kavya Sugur², Sophia Matossian¹, Katarina Kmetova³, Christine Goudsmit⁴, Jessica Turnier⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Saline, MI
Background/Purpose: Adults with dermatomyositis face a well-established 2–3-fold increased risk of major adverse cardiovascular events, driven by systemic inflammation, endothelial dysfunction, and treatment-related metabolic complications.…
Abstract Number: 2070 • ACR Convergence 2025
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Pranathi Bandarupalli¹, Vineeth Potluri², Amr Alemairy², Harsharn Grewal² and Shudipan Chakraborthy², ¹Mercy St Vincent Medical Center, Toledo, OH, ²Mercy Health St. Vincent Medical Center, Toledo, OH
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), including polymyositis and dermatomyositis, are rare systemic autoimmune disorders characterized by chronic muscle inflammation and progressive muscle weakness. Patients with…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].